Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
VolitionRx Limited (NYSE: VNRX) appointed Mickie Henshall to its board of directors effective August 15, 2022. Henshall brings over 20 years of marketing experience in the IVD and life science industries, previously holding key positions at Illumina and REALM IDx. The board believes her expertise will support Volition's commercialization efforts, particularly regarding its Nu.Q® technology. Henshall noted the company's potential to revolutionize diagnostics for life-altering diseases. Volition is focused on developing cost-effective blood tests for monitoring diseases, including cancer.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its second-quarter financial results for the period ending June 30, 2022. The company reported cash and cash equivalents of approximately $16.7 million, down from $20.6 million at year-end 2021. However, they secured $6.4 million via a public offering post-quarter and received $1.5 million in non-dilutive funding. Volition has made strides with the CE Mark for its Nu.Q® NETs test in Europe and is expanding clinical studies in the U.S. with MD Anderson and Diagnostic Oncology CRO LLC, aiming for FDA clearance in 2023.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study neutrophil extracellular traps (NETs) in cancer patients with sepsis. Led by Professor Jyotika Sharma, the study will utilize Volition's Nu.Q® NETs test, recently CE marked for NETosis evaluation. This research targets the critical early identification of sepsis risk in cancer patients, aiming to improve outcomes. High NET levels are linked to severe reactions and organ failure, emphasizing the test's potential in clinical settings.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Diagnostic Oncology CRO, LLC (DXOCRO) to lead development and clinical validation studies for its Nu.Q® product range in the U.S. The collaboration aims to establish clinical utility for its tests related to sepsis and cancer, ultimately seeking FDA clearance. DXOCRO brings expertise in commercialization and regulatory affairs to Volition, enhancing its strategy for U.S. market entry. This partnership supports Volition's objective to demonstrate the potential of its Nucleosomics™ technology in improving patient outcomes.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium. This funding will support an early access program for Volition's Nu.Q® product portfolio across the EU, UK, and USA. COO Gaetan Michel expressed excitement for advancing Nucleosomics™ technology and engaging industry leaders. The funding is part of over $14 million in grants from Walloon Region since 2016, and the loan will bear a 6% interest rate, repayable over four years, maturing on July 31, 2026.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the closing of its public offering of 3,450,000 shares at $2.00 each, raising gross proceeds of $6.9 million. The proceeds will be allocated for research, product development, clinical studies, and potential strategic acquisitions. The offering was facilitated by Newbridge Securities Corporation and is part of a previously filed shelf registration. The company focuses on developing blood tests to diagnose serious diseases using its Nucleosomics™ platform.
Xenetic Biosciences (NASDAQ: XBIO) and VolitionRx Limited (NYSE AMERICAN: VNRX) announced a collaboration to develop Neutrophil Extracellular Traps (NETs) targeted, adoptive cell therapies for cancer treatment. The program aims to evaluate the integration of Volition's Nu.Q® NETs Test with Xenetic's DNase-Armored CAR T platform to potentially address multiple solid tumor types. Volition will fund the research, sharing proceeds from commercialization. The collaboration highlights both companies' commitment to innovative cancer therapies and reflects Xenetic's recent acquisition of the DNase platform.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the pricing of its underwritten public offering of 3,000,000 shares at $2.00 per share, aiming to raise gross proceeds of approximately $6 million. An additional 450,000 shares may be purchased by the underwriter for overallotments. The offering is set to close around August 2, 2022. Proceeds will fund research, development, clinical studies, and working capital, including potential strategic acquisitions.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced an underwritten public offering of its common stock, with all shares offered by the company. The offering includes a 30-day option for the underwriter to purchase an additional 15% of shares at the public offering price. The exact terms will depend on market conditions, and there is no guarantee of completion. Newbridge Securities Corporation is the sole book-running manager. The offering is made under a shelf registration statement previously filed with the SEC. A preliminary prospectus has been filed and is available on the SEC's website.
VolitionRx Limited (NYSE AMERICAN: VNRX) presented new data on its Nu.Q® NETs test at the ISTH Congress on July 13, 2022. The research, conducted with the University of Namur and QUALIblood, explores NETosis biomarkers in sepsis and COVID-19. Key findings include a correlation between Nu.Q® NET levels and the SOFA score, potentially aiding in patient diagnosis. Volition's Chief Scientific Officer emphasized the significance of this congress for building collaborations and advancing clinical applications of Nu.Q® tests in Europe.